Introduction
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer death worldwide, with 1.09 million new cases and 0.77 million deaths in 2020 [
1]. There is a heavy burden of gastric cancer in Eastern Asia, which has the highest number of new cases (0.66 million, 60.6% of the total) and deaths (0.44 million, 57.1%) [
1].
Platinum-based or fluoropyrimidine-based chemotherapies are globally accepted first-line treatments for patients with gastric cancer [
2‐
6]. For patients with human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, trastuzumab combined with a chemotherapeutic agent is recommended [
2‐
6]. The recent introduction of immune checkpoint inhibitors (ICIs), such as nivolumab [
7], in combination with chemotherapy has led to improved patient survival and expanded the options available of first-line treatment panels.
When patients progress while receiving first-line therapies, chemotherapeutic agents, including docetaxel (DTX), paclitaxel (PTX), albumin-bound paclitaxel (nab-PTX), irinotecan (IRI), and fluoropyrimidine, are commonly used as second-line treatments [
8]. However, the median survival of patients receiving these chemotherapeutic agents is typically less than 6 months [
9‐
11]. Ramucirumab (RAM, brand name Cyramza) is a humanized monoclonal antibody that specifically targets the extracellular domain of the vascular endothelial growth factor (VEGF) receptor 2 [
12]. On the basis of the results of three phase 3 trials, REGARD [
12], RAINBOW [
13], and RAINBOW-Asia [
14], RAM has been approved worldwide, as monotherapy or in combination with PTX, for use as a second-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (G/GEA). RAM and RAM + PTX therapies are preferred or recommended as grade I level in guidance and have been widely used in clinical practice [
2‐
6].
Real-world studies (RWSs) have become an essential complement to randomized controlled trials (RCTs) for informing healthcare decision-making. Though the efficacy and safety of RAM [
12] and RAM + PTX [
13] have been established in phase 3 trials, the effectiveness and safety in real-world settings remain uncertain as clinical practice involves a diverse patient population. Therefore, a systematic literature review (SLR) of RWSs is necessary, particularly in Eastern Asia where gastric cancer poses a significant burden. This SLR aims to summarize the effectiveness and safety of RAM or RAM-based therapy in real-world settings in Eastern Asia in an effort to help guide future research endeavors.
Methods
This SLR followed the guidelines of the preferred reporting items for systematic review and meta-analyses (PRISMA) [
15], and the PRISMA checklist was used for verification (Supplementary Material Appendix 1 and 2). The SLR was registered in the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) (ID INPLASY2022120023, available from
https://inplasy.com/inplasy-2022-12-0023/). This review is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Eligibility Criteria
We only included RWSs that contained cohort studies, post-marketing surveillance/safety studies (PMSS), pragmatic clinical trials, and case series. Patients with unresectable advanced or metastatic G/GEA receiving RAM or RAM-based therapy as a second-line treatment in Eastern Asia were included. The selection criterium for second-line treatment was that at least 80% of patients received RAM or RAM-based therapy as a second-line treatment. In this study, Eastern Asia comprised Japan, Korea, and China, which includes Mainland China, Hong Kong, Taiwan, and Macau. RCTs, controlled clinical trials, and pre–post trials were not included. Studies that did not report outcomes of interest or those that were not in English or Chinese were also excluded.
Outcomes
The primary outcome of interest was effectiveness of treatment, including overall survival (OS) and progression-free survival (PFS). The secondary outcomes were drug utilization, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Drug utilization included relative dose intensity (RDI), treatment discontinuation (TD), duration of treatment (DoT), and post-discontinuation treatment (PDT). AEs referred to the incidence rate of any grade AEs and grade ≥ 3 AEs.
Search Strategy
Studies published between January 2014 and December 2021 were identified through computer-based searches in PubMed, Embase, and Cochrane Library without limitations on language. The following keywords were used in combination: (“stomach cancer” OR “gastric cancer” OR “gastroesophageal junction cancer” OR “gastroesophageal junction adenocarcinoma”) AND (“advanced” OR “metastatic” OR “unresectable”) AND (“ramucirumab” OR “Cyramza” OR “LY3009806”) AND (“Japan” OR “Korea” OR “China”). Complete search strategies are presented in Supplementary Material Appendix 3. We also searched the following three Chinese databases: CNKI, Wanfang, and CBM using the same search strategy as the one used in English databases except the keywords were translated into Chinese. Complete search strategies are presented in Supplementary Material Appendix 4 and 5.
Study Screening
Two reviewers screened studies on the basis of the titles and abstracts. All potentially relevant citations were requested and inspected in detail using the full-text version, where available. Disagreements were resolved by discussion with assistance from a third team member, if necessary. A PRISMA flow diagram was constructed to show the full-study selection process.
All data were extracted by two independent reviewers using a pre-defined data extraction form that included study characteristics (i.e., country, study design, and sample size), participant characteristics (i.e., age, gender, and location of metastasis), interventions, and outcomes. Discrepancies were resolved by consensus or by involving a third team member. Multiple reports of the same study were collated and judged on the basis of the population and intervention. We always chose the most recently published study with more participants or more comprehensive outcomes.
Assessment of Bias
Two reviewers independently assessed the risk of bias in the included studies. Disagreements were resolved by discussion with assistance from a third team member, if necessary. We used the Newcastle–Ottawa Scale (NOS) for controlled studies in which there was more than one treatment group [
16]. For non-controlled studies in which all patients received the same treatment, we used the “quality assessment tool for before–after (pre–post) studies with no control group” outlined by National Institutes of Health (NIH) to assess risk of bias [
17].
Data Summary
The characteristics of the included studies and patients along with data on the effectiveness and safety outcomes were summarized and presented using tables and figures. Proportions were used to report dichotomous outcomes data, while time-to-event outcomes data were reported as the median and 95% confidence interval [CI] or hazard ratio [HR]. The range of median RDI, proportion of TD, proportion of PDT, median DoT, median OS, median PFS, ORR, and DCR were summarized by treatment in all included studies. The comparative effectiveness (OS, PFS, ORR, DCR) of different treatments or subgroup of patients were subsequently described in comparative studies. The range of the overall incidence of AEs (any grade, grade ≥ 3), top five most frequently occurring AEs (any grade, grade ≥ 3), and AEs of special interest (grade ≥ 3) were summarized by treatment in all included studies. The comparative safety of different treatments or subgroup of patients were subsequently described in comparative studies. In this review, no distinctions were made between the terminology used to describe AEs and treatment-related adverse events (TRAEs) used in the original studies.
Discussion
To our knowledge, the present SLR, with a total of 23 studies that assess the effectiveness and safety of second-line RAM or RAM-based therapy in patients with unresectable advanced or metastatic G/GEA, provides the most comprehensive analysis of real-world evidence on RAM or RAM-based treatment in Japan and South Korea. This SLR indicates RAM + PTX is effective and associated with an acceptable toxicity profile. Compared to PTX, RAM + PTX appears to be associated with longer survival and a better response rate. Prior anti-PD-1 therapy exposure may enhance the effectiveness of RAM + taxane, but further research is needed.
In this SLR, the effectiveness data predominantly focused on RAM + PTX, presenting a range of values for median OS, median PFS, ORR, and DCR that aligned with the findings reported in both the RAINBOW trial [
13] and RAINBOW-Asia trial [
14], even after excluding data obtained from conference abstracts. Additionally, although there was limited data available for RAM, the range of values for median OS, median PFS, ORR, and DCR summarized in the SLR were also consistent with those reported in the REGARD trial [
12]. In the RAINBOW trial, patients receiving RAM + PTX had significantly longer median OS (9.6 vs. 7.4 months, HR 0.807, 95% CI 0.678–0.962,
p = 0.017) and median PFS (4.4 vs. 2.9 months, HR 0.635, 95% CI 0.536–0.752,
p < 0.0001), along with significantly higher ORR (28% vs. 16%,
p = 0.0001) and DCR (80% vs. 64%,
p < 0.0001) than those receiving PTX [
13]. These findings were further confirmed by the RAINBOW-Asia trial, a bridging study of RAINBOW, conducted predominantly on Chinese patients, demonstrating consistent efficacy of RAM + PTX [
14]. The SLR also supported the superior effectiveness of RAM + PTX over PTX. However, it should be noted that some comparative results in the original studies did not reach statistical significance. This could be attributed to the smaller sample size in RWSs compared to RCTs. In addition, the comparative effectiveness data of RAM + PTX vs. PTX in this SLR were derived from three retrospective cohort studies presented as conference abstracts. These studies lacked adequate descriptions of the statistical method employed and did not account for confounding factors, which are essential in analyzing comparative effectiveness. Consequently, caution should be exercised when interpreting the comparative results between RAM + PTX and PTX in this SLR. Peritoneal metastasis, malignant ascites, and old age are commonly associated with poor prognosis in patients with gastric cancer [
42‐
45]. Patients with these characteristics often have poor tolerance for and low sensitivity to chemotherapy. Despite these challenges, RAM + PTX therapy was found to be effective as well [
26,
29,
32].
The median RDI was 99% for RAM with a median DoT of 18.0 weeks in RAINBOW trial [
13] and the median RDI was 98.4% for RAM with a median DoT of 14.0 weeks in RAINBOW-Asia trial [
14]. This SLR found similar RDI and DoT ranges for patients treated with RAM + PTX. However, it is worth noting that the discontinuation rate due to AEs was slightly higher in both trials (12% for RAINBOW [
13] and 7% for RAINBOW-Asia [
14]) than in the SLR (5.3–6.3%). This difference may be attributed to the higher incidence of grade ≥ 3 AEs in the RAINBOW (81.7%) [
13] and RAINBOW-Asia (79.5%) [
14] trials than in the SLR (63.8%). Consistent with the results from these two trials, we found hematological toxicities were commonly observed AEs among patients treated with RAM + PTX. Gastrointestinal perforation, gastrointestinal hemorrhage, and thromboembolic events were AESI associated with anti-angiogenesis therapy. The RAINBOW trial reported grade ≥ 3 incidence rates of 1.2%, 3.7%, and 3.4% for these events, respectively [
13]. Similarly, in the RAINBOW-Asia trial, the rates were 0.0%, 2.7%, and 0.7% [
14]. These rates were generally lower in this SLR, except for two study with a small sample size (
n = 8,
n = 21), in which the incidence of gastrointestinal perforation was 12.5% [
40] and 10.0% [
21], respectively. This value should be interpreted with caution because of the potential bias inherent in the small sample size. Our findings regarding comparative safety are consistent with those of the RAINBOW trial and RAINBOW-Asia. In the RAINBOW trial, grade ≥ 3 neutropenia (40.7% vs. 18.8%) and leukopenia (17.4% vs. 6.7%) occurred more frequently with RAM + PTX than with PTX [
13]. Similarly, in the RAINBOW-Asia trial, the rates were 54.3% vs. 38.6% for grade ≥ 3 neutropenia and 43.3% vs. 29.0% for leukopenia. These results collectively provide evidence supporting a favorable safety profile for RAM.
From the perspective of AEs, treatment with RAM + nab-PTX has been conditionally recommended by Japanese gastric cancer treatment guidelines (JGCG) when nab-PTX is preferred over PTX [
3]. Our findings suggest RAM + nab-PTX and RAM + PTX are comparable in terms of effectiveness and safety and support the use of RAM + nab-PTX as a second-line treatment option for patients with gastric cancer [
24,
26]. In this SLR, one study indicated RAM + nab-PTX was associated with longer PFS than RAM + PTX in patients with peritoneal metastasis [
26]. Conversely, data from a recently disclosed phase 2 trial (P-SELECT) in Japan showed no significant difference between the two regimens in terms of OS, PFS, ORR, and DCR, irrespective of the presence or absence of peritoneal metastasis [
46]. More evidence might be needed to further evaluate whether patients with peritoneal metastasis can benefit more from RAM + nab-PTX or RAM + PTX.
In this SLR, most patients were given fluoropyrimidine-containing and/or platinum-containing regimens in first-line treatment. Although three studies included a few patients who received prior fluoropyrimidine plus taxanes chemotherapy, no effectiveness or safety data were available for the subgroup of patients [
19,
27,
34].
ICIs combined with chemotherapeutic agents as a first-line treatment have been shown to improve the survival of patients with advanced G/GEA in the phase 3 Checkmate-649 [
7] and ATTRACTION-4 [
47] trials. Following this initial treatment, RAM was administered as one of the subsequent therapies in these studies. Unlike the ATTRACTION-4, the Checkmate-649 also provided PFS2 results, which measured the time from randomization to progression after subsequent systemic therapy, initiation of second subsequent systemic therapy, or death, whichever occurred earlier. In the Checkmate-649, the median PFS2 benefit was observed with nivolumab + chemotherapy vs. chemotherapy (12.2 vs. 10.4 months, HR 0.75, 95% CI 0.67–0.84) [
48]. This suggests nivolumab + chemotherapy may improve the efficacy of second-line treatments, including RAM. However, data were not available for the subgroup of patients who received RAM as a second-line treatment in the Checkmate-649 trial. It is worth noting that there is another recently published subgroup analysis of a phase 3 clinical trial which analyzed the effect of RAM after pre-treatment with ICIs, with results suggesting that RAM plus irinotecan is an effective subsequent treatment after ICIs progression [
49]. One study included in this SLR showed patients with prior anti-PD-1 exposure who subsequently received RAM + taxane had significantly improved PFS, ORR, and DCR with an acceptable toxicity profile when compared with patients without prior anti-PD-1 exposure [
22]. In addition, a recent RWS by Kankeu Fonkoua et al. conducted in the USA demonstrated patients with prior ICIs receiving RAM + PTX as a second-line or later therapy had significantly improved OS (14.8 vs. 7.4 months, HR 0.33, 95% CI 0.15–0.72), PFS (8.9 vs. 4.9 months, HR 0.37, 95% CI 0.15–0.91), and ORR (57.9% vs. 17.7%,
p < 0.0001) when compared with patients without prior ICIs [
50]. Our findings support the notion that patients with prior anti-PD-1 therapy may benefit more from RAM treatment. Recent studies have illuminated the potential mechanisms underlying these findings. In addition to promoting tumor vessel growth, VEGF also suppresses the immune system by inhibiting the function and recruitment of T-cells, promoting the recruitment of regulatory T cells and myeloid-derived suppressor cells (MDSCs), as well as inhibiting the differentiation and activation of dendritic cells. As an anti-VEGF targeted agent, RAM may address these issues, thus overcoming anti-PD-1 resistance [
51,
52]. However, more extensive research is needed to confirm these observations as result of the limited evidence currently available.
Strengths: This is the first SLR to summarize the real-world effectiveness and safety of RAM as a second-line therapy for the treatment of patients with unresectable advanced or metastatic G/GEA in Japan and South Korea since its first approval in 2014. These findings, as an essential complement to randomized controlled clinical trial data, will provide valuable insights for clinicians treating patients with advanced or metastatic G/GEA, especially in Eastern Asia.
Limitations: The first limitation is the literature search of this SLR was up to December 2021. The authors conducted an additional quick literature search using the same search strategy, with the publication date limited from January 1, 2022 to January 22, 2024. After screening, there were only two studies published in 2022 from Japan met the inclusion/exclusion criteria and the two studies did not provide additional data that would have a substantial impact on the key results and conclusion of the current manuscript. Secondly, only half of the included RWSs were full-text studies, and most were retrospective cohort studies with small sample size or limited information on statistical methods used. This somewhat diminishes the credibility of the comparative effectiveness results. As a result of these limitations, we relied on descriptive methods instead of meta-analysis to address research questions, which itself is a limitation. Thirdly, although the use of ICIs in first-line treatments are increasing these days, there were few RWSs evaluating the impact of ICIs on the effectiveness and safety of RAM or RAM-based therapy in the second-line setting. Lastly, we aimed to summarize the relevant real-world evidence in Eastern Asia; unfortunately, none of the included studies were conducted in China, which has a large population of patients with gastric cancer. This is possibly because RAM has only been approved in Mainland China for 1 year.
Recognizing these limitations can guide future research efforts to generate more evidence and address uncertainties in the management of advanced or metastatic G/GEA. It is encouraging to note that a prospective observational PMSS of RAM in Chinese patients with G/GEA is ongoing (EU PAS Register Number EUPAS47676) [
53], and more real-world data are expected soon.